Abbott Reports Second-Quarter Results    

With results ahead of expectations, Abbott's is among top healthcare companies raising its outlook for 2018.

Strategy and Strength|Jul.18, 2018

Abbott's second-quarter results are in, and we delivered another strong quarter in healthcare sector growth thanks to a strong product pipeline and outstanding execution by our management team.

For the quarter, Abbott beat Street estimates on the top and bottom line, delivering impressive organic sales and double-digit EPS growth. Today's results extend our decade-long streak of meeting or beating Street-adjusted EPS estimates every quarter.

And, with all four of our businesses — Diagnostics, Devices, Nutrition and Medicines — contributing to strong growth in the quarter, Abbott announced plans to raise its outlook for the rest of the year.

The strong healthcare sector growth we're achieving is a direct result of the strategic steps we've taken to position the company in the most attractive areas of healthcare and the productivity of our life-changing technologies.

What follows is just a few of our highlights from the quarter:

  • XIENCE Sierra, the newest generation of our gold-standard coronary stent system, was approved in the U.S. and received national reimbursement in Japan.
  • Advisor HD Grid Mapping Catheter, Sensor Enabled, which includes a first-of-its-kind configuration to create highly detailed maps of the heart to help physicians perform cardiac ablation procedures, was approved in the U.S.
  • FreeStyle Libre™, our revolutionary continuous glucose monitor, continues to have unparalleled uptake. New real-world evidence from more than 250,000 FreeStyle Libre users showed that increased scanning is associated with improved glucose control.
  • Ensure® Max Protein was launched in the U.S., helping people refuel their bodies with 30 grams of high-quality protein and 1 gram of sugar.

For full financials, you can read our press release, but major highlights are included in the materials below:

Abbott's Chairman and CEO Miles D. White shared his views on second-quarter performance:

Learn more about Abbott’s second-quarter 2018 results:

Download a summary of Abbott's earnings highlights here

Abbott Reports Second-Quarter Results

For more information on Abbott's earnings results, see the news release

* Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.


The FreeStyle Libre Flash Glucose Monitoring system is a continuous glucose monitoring (CGM) device indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The system is intended for single patient use and requires a prescription.


Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.


Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The FreeStyle Libre system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The FreeStyle Libre system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit for detailed indications for use and safety information